Abaza Y, Fathi AT. Monoclonal antibodies in acute myeloid leukemia–Are we there yet? Cancer J 2022;28(1):37-42. Abstract
Amonoo HL et al. Posttraumatic stress disorder symptoms in patients with acute myeloid leukemia. Cancer 2021;127(14):2500-6. Abstract
El-Jawahiri A et al. Effectiveness of integrated palliative and oncology care for patients with acute myeloid leukemia: A randomized clinical trial. JAMA Oncol 2021;7(2):238-45. Abstract
Fathi AT et al. Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia. Am J Hematol 2021;96(6):735-46. Abstract
Levis MJ et al. Phase 1 first-in-human study of irreversible FLT3 inhibitor FF-10101-01 in relapsed or refractory acute myeloid leukemia. ASCO 2021;Abstract 7008.
Montesinos P et al. AGILE: A global, randomized, double-blind, phase 3 study of ivosidenib + azacitidine versus placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation. ASH 2021;Abstract 697.
Ott A et al. Arsenic toxicity manifesting as profuse watery diarrhea during induction therapy for acute promyelocytic leukemia. Clin Case Rep 2021;9(5):e04115. Abstract
Perl AE et al. Follow-up of patients with FLT3-mutated R/R AML in the phase 3 ADMIRAL trial. ASCO 2021;Abstract 7013.
Röllig C et al. Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: Long-term follow-up of the randomized controlled SORAML trial. Leukemia 2021;35(9):2517-25. Abstract
Sorror ML et al. Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. Blood 2021;138(5):387-400. Abstract
Stein EM et al. Updated survival and response analyses from a phase 1 study of ivosidenib or enasidenib combined with induction and consolidation chemotherapy in patients with newly diagnosed AML with an IDH1 or IDH2 mutation. ASH 2021;Abstract 1276.
Vaughn DM et al. Factors associated with health care utilization at the end of life for patients with acute myeloid leukemia. J Palliat Med 2021;[Online ahead of print]. Abstract
Wei AH et al. 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150). Blood Cancer J 2021;11(10):163. Abstract
Wei AH et al. Long-term overall survival (OS) with oral azacitidine (Oral-AZA) in patients with acute myeloid leukemia (AML) in first remission after intensive chemotherapy (IC): Updated results from the phase 3 QUAZAR AML-001 trial. ASH 2021;Abstract 871.